Literature DB >> 28431238

Reducing Recurrence of C. difficile Infection.

Michael G Dieterle1, Vincent B Young2.   

Abstract

Clostridium difficile infection (CDI) is facilitated by alteration of the microbiome following antibiotic administration. Antimicrobial therapy directed against the pathogen can treat CDI. Unfortunately, ∼20% of successfully treated patients will suffer recurrence. Bezlotoxumab, a human monoclonal antibody, binds to C. difficile toxin B (TcdB), reducing recurrence presumably by limiting epithelial damage and facilitating microbiome recovery.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28431238     DOI： 10.1016/j.cell.2017.03.039

Source DB:  PubMed          Journal:  Cell        ISSN： 0092-8674            Impact factor:   41.582


  11 in total

Review 1.  Novel therapies and preventative strategies for primary and recurrent Clostridium difficile infections.

Authors:  Michael G Dieterle; Krishna Rao; Vincent B Young
Journal:  Ann N Y Acad Sci       Date:  2018-09-21       Impact factor: 5.691

2.  Transcriptional response of Clostridium difficile to low iron conditions.

Authors:  Jessica L Hastie; Phillip C Hanna; Paul E Carlson
Journal:  Pathog Dis       Date:  2018-03-01       Impact factor: 3.166

Review 3.  Understanding Clostridium difficile Colonization.

Authors:  Monique J T Crobach; Jonathan J Vernon; Vivian G Loo; Ling Yuan Kong; Séverine Péchiné; Mark H Wilcox; Ed J Kuijper
Journal:  Clin Microbiol Rev       Date:  2018-03-14       Impact factor: 26.132

4.  Detection of Newly Secreted Antibodies Predicts Nonrecurrence in Primary Clostridioides difficile Infection.

Authors:  F Eun-Hyung Lee; John L Daiss; Natalie S Haddad; Sophia Nozick; Geena Kim; Shant Ohanian; Colleen S Kraft; Paulina A Rebolledo; Yun Wang; Hao Wu; Adam Bressler; Sang Nguyet Thi Le; Merin Kuruvilla; Martin C Runnstrom; Richard P Ramonell; L Edward Cannon
Journal:  J Clin Microbiol       Date:  2022-03-16       Impact factor: 11.677

Review 5.  Influence of Microbiota on Intestinal Immune System in Ulcerative Colitis and Its Intervention.

Authors:  Sai-Long Zhang; Shu-Na Wang; Chao-Yu Miao
Journal:  Front Immunol       Date:  2017-11-28       Impact factor: 7.561

Review 6.  Advances in the diagnosis and treatment of Clostridium difficile infections.

Authors:  Zhong Peng; Lifen Ling; Charles W Stratton; Chunhui Li; Christopher R Polage; Bin Wu; Yi-Wei Tang
Journal:  Emerg Microbes Infect       Date:  2018-02-07       Impact factor: 7.163

Review 7.  Application of Antibody-Mediated Therapy for Treatment and Prevention of Clostridium difficile Infection.

Authors:  Beatrix Förster; Pui Khi Chung; Monique J T Crobach; Ed J Kuijper
Journal:  Front Microbiol       Date:  2018-06-25       Impact factor: 5.640

8.  Consortium of Probiotics Attenuates Colonization of Clostridioides difficile.

Authors:  Xianping Li; Qiongfang Chu; Yuanming Huang; Yuchun Xiao; Liqiong Song; Siyi Zhu; Ying Kang; Shan Lu; Jianguo Xu; Zhihong Ren
Journal:  Front Microbiol       Date:  2019-12-12       Impact factor: 5.640

9.  Structural dynamics of receptor recognition and pH-induced dissociation of full-length Clostridioides difficile Toxin B.

Authors:  Mengqiu Jiang; Joonyoung Shin; Rudo Simeon; Jeng-Yih Chang; Ran Meng; Yuhang Wang; Omkar Shinde; Pingwei Li; Zhilei Chen; Junjie Zhang
Journal:  PLoS Biol       Date:  2022-03-24       Impact factor: 8.029

10.  A novel probiotic therapeutic in a murine model of Clostridioides difficile colitis.

Authors:  Rita D Shelby; Grace E Janzow; Lauren Mashburn-Warren; Jeffrey Galley; Natalie Tengberg; Jason Navarro; Miriam Conces; Michael T Bailey; Steven D Goodman; Gail E Besner
Journal:  Gut Microbes       Date:  2020-11-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.